Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global.
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide
PLEASANTON, Calif., Dec. 20, 2023 /PRNewswire/ 10x Genomics, Inc., , a leader.
10X Genomics Launches Xenium Catalyst Network menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a.